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This article reviews the literature on the application of methods for the detection of growth
factors, oncogene proteins, and tumor-suppressor gene proteins in the blood of humans with
cancer or who are at risk for the development of cancer. The research summarized here suggests
that many of these biomarker assays can be used to distinguish between diseased and
nondiseased states and in some instances may be able to predict susceptibility for future
disease. Thus, these biomarkers could be valuable tools for monitoring at-risk populations for
purposes of disease prevention and control. - Environ Health Perspect 105(Suppl 4):807-816
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Introduction
The development of many cancers and
some other environmentally related dis-
eases is believed to be associated with the
aberrant expression of genes that encode
proteins involved in cellular growth signal
transduction, including growth factors and
the protein products of oncogenes and
tumor-suppressor genes. This aberrant
expression can involve a quantitative differ-
ence from normal (i.e., overexpression of
the wild-type protein) and/or a qualitative
difference (i.e., expression of a mutant
form of the protein). The detection of
increased expression of these proteins or
expression of mutant forms of these
proteins therefore represents a category of
potential biomarkers with which to study
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susceptibility to the development of
disease, particularly cancer.
Numerous studies have documented
this aberrant expression ofgrowth factors
and oncoproteins in diseased tissue com-
pared to normal tissue. However, the tech-
niques are somewhat complicated, and, in
most cases, it would be difficult to obtain
tissue samples for routine screening ofat-
risk populations. Fortunately, in many
instances it is apparent that these proteins
gain access to the extracellular environment
and are thus detectable in easily obtainable
biological fluids such as serum or plasma
by techniques that are relatively simple,
convenient, and easily standardized. Thus,
this review will focus on the assay of
growth factors and oncoproteins in extra-
cellular fluids, particularly serum and
plasma, by techniques that could readily be
applied to study at-risk populations in
developing as well as developed countries.
Growth Factors
Since growth factors are normally actively
secreted from cells, they represent logical
targets for detection in blood during
disease development. Several studies have
demonstrated differences in blood levels of
growth factors between cancer patients
and controls.
Platelet-derived Growth Factor
Platelet-derived growth factor (PDGF),
which functions as a dimer of A and B
chains (PDGF-B is encoded by the sis
oncogene), has been examined in the blood
ofvarious cancer patients. Plasma PDGF-B
chain levels were determined by enzyme-
linked immunosorbent assay (ELISA) in
131 patients with cancers ofvarious types
(including carcinomas, sarcomas, and lym-
phomas) and 72 noncancer controls (1).
Levels were greater than the highest control
value of 0.69 ng/ml in 19 (15%) of the
cases, although, based on other markers, in
only 5 (4%) ofthe cases was the tumor felt
to be the source of the growth factor.
Plasma PDGF levels have also been deter-
mined by radioimmunoassay (RIA) in 58
breast cancer patients and 9 normal female
controls (2). All ofthe controls were below
the lower limit of detection of the assay
(1.56 fmol/100 1l), but 20 of 17 (12%)
stage II cancer patients had detectable lev-
els and 13 of 41 (32%) stage IV cancer
patients had elevated levels (defined as
more than twice the lower limit of detec-
tion of the assay). Patients with elevated
PDGF had a significantly greater degree of
metastatic involvement and a significantly
shorter survival time. Elevated levels of
PDGF-related proteins have also been
detected by immunoblotting in the urine
ofcancer patients (3).
Transforming Growth Factor (x
Transforming growth factor cc (TGFa) is a
50-amino acid, single-chain polypeptide
growth factor, and its proliferative effect is
mediated through the epidermal growth
factor receptor. TGFx, as determined by
ELISA in plasma, was initially reported to
be elevated in 71 patients with solid tumors
(mean ± SD = 346 ± 155 pg/ml) compared
to 66 controls (mean ± SD = 187± 29
pg/ml); but the differences were not statis-
tically significant (4). In another study,
TGFca levels in pooled plasma samples
determined by ELISA were 0.051 ng/ml in
cancer patients (stomach, colon, liver)
compared to 0.028 ng/ml in 15 healthy
volunteers (5). TGFx levels have also been
measured by RIA in the serum of83 breast
cancer patients and 74 healthy controls (6).
Among the controls, 24 had nondetectable
serum TGFa (< 100 pg/mr) and 50 (67%)
had detectable levels that ranged from 120
to 207 pg/ml (mean±SD= 147± 18 pg/ml).
All ofthe cancer cases had detectable serum
TGFa levels that ranged from 210 to 740
pg/ml (mean ± SD = 353 ± 98 pg/ml), and
the difference in the means between cases
and controls was statistically significant
(p< 0.001). The same RIA was also used to
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compare these control levels to serum
TGFa in 100 patients with gastrointestinal
cancers (esophageal, gastric, pancreatic,
colonic, rectal) which ranged from 119 to
760 pg/ml (mean ± SD=269 ± 102 pg/ml)
(7). Once again, the difference in the
means between cases and controls was sta-
tistically significant (p< 0.001), and both
early and late stage cancer patients had ele-
vated levels. In a study ofbanked serum
samples in asbestosis patients, elevated
serum TGFa levels by ELISA (defined as
greater than the control mean plus 2 SD)
were found in 13 of 36 (36%) patients
who subsequently developed cancer com-
pared to 27 of71 (38%) asbestosis patients
who had not yet developed cancer and 0 of
10 (0%) nonasbestosis controls, and several
cases had elevated serum levels years prior
to the detection ofclinical disease (8).
TransforningGrowth Factor [3
Transforming growth factor [B (TGF[) is a
family ofdisulfide-linked polypeptides with
a molecular weight of 25 kDa for which
five subtypes have been identified. TGF[1
levels were determined by ELISA and by a
biological activity assay (growth inhibition
ofmink lung epithelial cells) in plasma of
26 hepatocellular carcinoma patients, 12
chronic hepatitis patients, 11 cirrhotics, and
20 normal controls (9,10). Mean levels
were statistically significantly higher in the
cancer cases (mean ±SD = 19.3 ± 19.5
ng/ml) compared to the chronic hepatitis
patients (mean ±SD =3.0 ±3.1 ng/ml), cir-
rhotics (mean ±SD = 3.7 2.1 ng/ml), or
controls (mean ±SD = 61.4± 0.8 ng/ml)
(p<0.01). Furthermore, in seven cancer
cases, following therapy by embolization
and/or resection, levels decreased sig-
nificantly (from 22.6± 16.7 ng/ml to
10.2 ±6.5 ng/ml; p<0.05), suggesting that
the tumor was the source of the elevated
levels of growth factor in the plasma. In
another study, TGFP levels measured by
ELISA and a biological activity assay were
found to be statistically significantly
elevated (p = 0.01) in 6 chronic myel-
ogenous leukemia patients in accelerated
or blast phase (mean ±SD = 4.3 ± 3.8
ng/ml) compared to 12 normal controls
(mean±SD =2.6± 1.1 ng/ml) (11). A third
study measured TGF[2 levels by ELISA in
the serum of 25 bladder cancer patients
and 5 healthy controls (12). Nine patients
with invasive cancer were found to have
elevated serum TGF[2 (69-155 pg/mi),
while the values ofpatients with superficial
bladder cancer were within the normal
range (<62 pg/ml). In a more recent study,
TGFP1, TGFP2, and TGF,3 levels were
measured by ELISA in the plasma of 28
breast cancer patients and 42 normal con-
trols (13). Control values ranged from 2 to
12 ng/ml (mean ±SD = 4.1 ±2.0 ng/ml),
and 2 of the cancer patients (7%) were
found to have elevated levels (defined as
more than 2 SD above the control mean).
TGF02 was detectable in 2 of the cancer
patients also, but not in any ofthe controls.
BasicFibroblast Growth Factor
Basic fibroblast growth factor (bFGF) is a
single-chain polypeptide composed of 146
amino acids. Basic fibroblast growth factor
was initially reported to be detectable by
ELISA in the serum ofrenal cell carcinoma
patients (14). Follow-up study showed
detectable levels (>30 pg/ml) in serum in
28 of 52 (54%) renal cell carcinoma
patients, 8 of 30 (27%) urothelial cancer
patients, 2 of 7 (29%) prostatic cancer
patients and 0 of 12 (0%) testicular cancer
patients (15). Five of 8 patients with renal
cell carcinoma who underwent selective
renal venous sampling prior to nephrec-
tomy had increased serum bFGF in the
renal vein from the affected kidney.
Within 2 weeks ofresection, serum bFGF
became nondetectable, suggesting that the
tumors were the source of the increased
bFGF in serum in those cases. Using an
enhanced chemiluminescence enzyme
immunoassay, elevated serum bFGF levels
(defined as more than 3 SD above the nor-
mal mean, i.e., >22.1 pg/ml) were found in
0 of25 (0%) controls, 0 of 16 (0%) stom-
ach cancers, 0 of6 (0%) bladder cancers, 2
of 23 (9%) liver cancers, 9 of 16 (56%)
brain cancers, 21 of 30 (70%) renal can-
cers, and 19 of 24 (79%) lung cancers
(16). Mean serum bFGF levels determined
by fluorometric enzyme immunoassay were
also significantly elevated in cases of
esophageal, stomach, colon, liver, breast
cancer (p< 0.001) and pancreas cancer
(p<0.01). Relatively high levels were found
in 1 patient with adenocarcinoma of the
lung, 4 of6 cases oflymphoma, and several
cases of gall bladder and thyroid cancer
(17). A follow-up study in breast cancer
patients showed serum bFGF levels higher
than those ofany normal controls in 25 of
35 (71%) stage I patients, 10 of 13 (77%)
stage II patients and 5 of 5 (100%) stage
III patients (18). Furthermore, in all
patients undergoing surgical resection,
serum levels were statistically significantly
lower after surgery than before, suggesting
that the tumors were the source of the
increased bFGF in serum in those cases.
Levels ofbFGF have also been reported to
be elevated in the serum in other breast
cancer patients (19), in the plasma of
patients with multiple endocrine neoplasia
type I (20) and of patients with B-cell
chronic lymphocytic leukemia (21), and in
the serum ofpatients with cervical cancer
(22). In the latter study, four of the 20
patients relapsed after complete remission
and two ofthese had a continuous increase
in serum bFGF levels before the clinical
detection of relapse with a mean lead time
of4 months, suggesting that serum bFGF
may be useful for the early detection of
recurrences and possibly primary tumors.
Other
Plasma or serum levels of several other
growth factors have been reported in vari-
ous cancers. Epidermal growth factor
(EGF) is elevated in the serum of some
patients with stomach cancer (23), cancer
of the tongue (24), and ovarian cancer
(25), but unchanged or decreased in other
cancers (26-28). Insulinlike growth fac-
tors, (IGF) have been reported to be ele-
vated in the plasma ofsome breast cancer
patients (29) and ovarian cancer patients
(25), but not in other cancers (30,31).
Elevated serum levels ofhepatocyte growth
factor (HGF) have been reported in hepato-
cellular carcinoma as well as in nonmalig-
nant liver diseases (32). In addition, many
types ofgrowth factors have been identified
in other biological fluids, including urine
(33), effusions (34), cyst aspirates (35,36),
and bronchoalveolar lavage (37).
Growth factors probably also play
important roles in non-cancer proliferative
diseases, such as fibroproliferative disor-
ders; and serum or plasma levels have been
determined in some cases. For example,
elevated TGF[ levels in plasma after
induction chemotherapy are predictive of
liver and lung fibrosis in patients receiving
bone marrow transplantation for cancer
(positive predictive value > 0.90) (38).
Elevated serum levels ofTGF[ have also
been reported more frequently in firefight-
ers, particularly those with a history of
asbestos exposure and chest radiographs
consistent with asbestos exposure, com-
pared to matched controls (39). Similarly,
elevated serum levels of PDGF were
reported in 25 of45 (56%) pneumoconio-
sis patients, and elevated levels were statis-
tically significantly more frequent in
radiographically advanced cases compared
to less advanced cases (p=0.016) with a
tendency for these cases to have progres-
sion oftheir fibrotic disease over the course
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of the study (40). Finally, in athero-
genesis, high levels of total growth factor
activity in plasma, 20% ofwhich is attrib-
utable to PDGF, has been found to be
significantly correlated with progression
(r= 0.42, p< 0.05) and severity (r= 0.52,
p< 0.01) of coronary atherosclerosis with
elevated PDGF levels specifically correlated
with the number and severity of stenoses
(r=0.40,p<0.05) (41).
Oncoproteins
Growth Factor Receptors
Transmembrane growth factor receptors are
frequently overexpressed in human malig-
nancies. Overexpression is accompanied in
many instances bycleavage ofthe extracellu-
lar domain (ECD) ofthe receptor with its
accumulation in the extracellular environ-
ment. Thus, detection ofincreased amounts
ofthe ECD ofthese receptors in blood is a
potential biomarker ofcancer development.
Many studies have examined the ECD
of the p185 transmembrane growth factor
receptor (encoded by the c-erbB-2 onco-
gene) in the blood of cancer patients. An
initial study reported elevated serum erbB-
2 ECD levels by ELISA (40- to 190-fold
higher than controls) in 3 of 12 (25%)
breast cancer patients compared to 35 con-
trols (42). Two ofthe cases with serum ele-
vation also had increased tissue expression,
suggesting that the tumors were the source
of the serum proteins. Another study
reported elevated serum erbB-2 ECD by
ELISA (defined as greater than 2 SD above
the mean ofnormals) in 3 of42 (7%) nor-
mal women, 5 of 33 (15%) women with
untreated primary breast cancer, and 24 of
105 (33%) women with metastatic breast
cancer (43). In another study, elevated
serum erbB-2 ECD by ELISA was detected
in 0 of30 (0%) cases ofbenign breast dis-
ease, 2 of 64 (3%) cases ofstage I/WI pri-
mary breast cancer, 5 of 17 (29%) cases of
stage III/IV primary breast cancer, 3 of 12
(33%) cases of locally recurrent breast
cancer, 26 of 51 (51%) cases of recurrent
metastatic disease, but 0 of 57 (0%) cases
with no evidence of recurrence; in addi-
tion, there was a close association between
serum elevation and tissue overexpression,
and in several cases changes in serum levels
reflected the clinical status of disease
(44,45). Similarly, 12 of 53 (23%)
patients with metastatic or locally advanced
breast cancer were reported to have ele-
vated levels ofserum erbB-2 ECD by RLA
compared to 0 of69 (0%) controls; in two
cases, changes in serum levels correlated
with disease status during therapy (46).
Another study reported elevated serum
erbB-2 ECD levels by ELISA in 0 of 19
(0%) controls, 0 of35 (0%) patients with-
out metastatic disease following removal of
the primary breast tumor, and 9 of 26
(35%) patients with residual metastatic
disease, 3 ofwhom had correspondingly
elevated tumor tissue expression (47).
Pupa et al. reported elevated serum
erbB-2 ECD levels by RIA in 0 of50 (0%)
healthy controls and 0 of 25 (0%) breast
cancer cases with stage I/II disease com-
pared to 6 of 40 (15%) cases with stage
III/IV disease, and the correlation between
tumor overexpression and serum elevation
was statistically significant (p<0.01) (48).
Kath et al. (49,50) reported elevated serum
erbB-2 ECD levels by ELISA in 26 of 61
(43%) patients with metastatic breast
cancer, and there was reasonably good cor-
relation between serum and tissue levels of
expression and with clinical course of dis-
ease (49,50). Breuer et al. found 1 of 25
(4%) matched controls had elevated serum
erbB-2 ECD by ELISA compared to 9 of
36 (25%) cases with newly diagnosed pri-
mary breast cancer (p=0.03); 2 cases with
elevated serum levels had tumor tissue
overexpression and two cases with elevated
preoperative levels had normal postopera-
tive levels (51,52). In addition, in this
study, there were 7 cases of in situ carci-
noma without invasion, and 3 of these
(43%) had elevated serum ECD levels,
suggesting that this may be a biomarker of
early malignant disease in certain cases of
breast cancer. Many additional studies on
elevated serum erbB-2 ECD in breast
cancer have been reported (53-59). In the
most recent study, elevated serum erbB-2
ECD was found in 3 of 66 (5%) controls,
0 of 12 (0%) cases ofbenign breast disease,
1 of 13 (8%) preoperative breast cancer
cases, 2 of 62 (3%) postoperative cases
without recurrent disease, and 55 of 93
(59%) cases with recurrent disease; elevated
serum level was statistically significantly
associated with protein overexpression in
the tumor (p=0.044) (60). An inducible
immune response to c-erbB-2 oncoprotein
(production ofantibodies against the pro-
tein from circulating lymphocytes isolated
and transformed with Epstein-Barr virus)
has also been identified in breast cancer
patients (61).
Elevated serum erbB-2 ECD levels have
also been identified in other cancers. In
ovarian cancer, elevated levels were
reported in 7 of48 (15%) patients with a
correlation between serum and tissue
overexpression (62). Elevated serum erbB-2
ECD levels were reported in ovarian can-
cers as well as colorectal, pancreatic,
prostate, and liver cancers (63). Similarly,
patients with gastric cancer have been
found to have elevated levels with a good
correlation between serum and tissue over-
expression (64-66). In another study, lev-
els in the plasma of colonic adenoma
patients were statistically significantly ele-
vated compared to controls; patients with
large adenomas had higher levels than
patients with small adenomas (67). In
addition, the average serum erbB-2 ECD
level in male Taiwanese who subsequently
developed hepatocellular carcinoma was
statistically significantly elevated compared
to matched controls who did not develop
cancer, and increasing levels showed a sig-
nificant linear trend in relation to the sub-
sequent development ofcancer, with those
individuals with elevated levels averaging
over 2 years between the time ofserum col-
lection and the diagnosis of disease
(68,69). These results support the hypoth-
esis that serum erbB-2 ECD may be a bio-
marker of early malignant disease in some
cases. Elevated serum erbB-2 ECD levels
have also been described in patients with
lung cancer (70). In another study, levels
measured in multiple banked serum sam-
ples from 11 pneumoconiosis patients who
subsequently developed lung cancer were
found to be statistically significantly ele-
vated compared to controls, and in 4 ofthe
cases, levels were elevated prior to the diag-
nosis ofdisease with a lead time averaging
35 months (71). This similarly supports
the potential utility of this biomarker for
the earlydiagnosis ofmalignant disease.
Recently, the ECD of the epidermal
growth factor receptor (EGFR, encoded by
the c-erbB-1 oncogene) has also been iden-
tified in cancer patients. The EGFR ECD
was quantitated by ELISA in the banked
serum samples from 38 asbestosis cases
who subsequently developed cancer, 72
asbestosis controls without cancer matched
for age, sex, race, smoking, and asbestos
exposure, and 20 nonasbestosis, non-
cancer controls matched for age, sex, race,
and smoking (72,73). The mean serum
level for the EGFR ECD in the cancer cases
(mean ±SD = 636± 299 fm/ml) was sta-
tistically significantly elevated (p<0.05) in
comparison to the mean level in the
asbestosis controls (mean ± SD = 546 ± 147
fm/ml or the nonasbestosis controls
(336 ± 228 fm/ml). Seven cancer cases had
elevated serum levels prior to the time of
disease diagnosis with an average lead time
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of 5.1 years, suggesting that this too may
be a potential biomarker ofearly malignant
disease. Serum EGFR ECD levels have also
been found to be statistically significantly
elevated among 22 former uranium miners
with lung cancer compared to 7 healthy
controls (p= 0.007) (74). The ECD of
EGFR has also been measured in the urine
of cancer patients. Elevated levels were
detected in 15 of42 (36%) squamous cell
carcinoma patients compared to 8 of 50
(16%) non-squamous cell carcinoma
patients and 3 of50 (6%) non-cancer con-
trols, statistically significant differences
(p<0.03) (75).
OtherOncogene Proteins
Although the mechanism by which they
gain access to the extracellular environ-
ment is uncertain, several nonreceptor
oncogene proteins, including the mem-
brane-associated G proteins and the
nuclear DNA-binding proteins, have been
identified in blood.
The ras oncogene encodes a 21-kDa
membrane-associated G protein (p2l)
involved in growth signal tranduction from
transmembrane growth factor receptors to
cytoplasmic kinases and ultimately to the
nucleus. The ras oncogene is activated in
carcinogenesis either by overexpression of
p21 or by expression of point-mutated
forms ofp21. The p21 ras-related protein
was elevated in serum by ELISA in 5 of34
(15%) patients with early stage malignan-
cies and 26 of 59 (44%) patients with
advanced malignancies compared to 1 of
58 (2%) controls, with the highest levels in
patients with lymphoma, breast, and uro-
genital malignancies (76,77). In another
study, increased serum p21 by ELISA was
found in 3 of 13 (23%) patients with
stomach cancer compared to 0 of 3 (0%)
normal controls, although no increases
were noted in 29 other patients with differ-
ent cancers (78). Elevated serum p2l has
also been identified in individuals at risk
for the development ofcancer due to work-
place carcinogen exposures (79-81). In
one ofthese cases, an individual with ele-
vated serum p21 by immunoblotting 18
months later developed a premalignant
colonic lesion, and once the lesion was
removed the individual's serum p21
returned to normal (82). This suggests that
the tumor was the source for the elevated
protein in serum and that this biomarker
may be detectable prior to the identi-
fication ofclinical disease. Elevated serum
p21 has also been identified in lung cancer
patients (83,84). In another study of
multiple-banked serum samples from 46
pneumoconiosis patients, elevated serum
p21 levels were demonstrated by
immunoblotting in 7 of 18 (39%) patients
who developed cancer (5 ofwhich were
lung cancers) compared to 2 of 28 (7%)
patients who did not develop cancer, a sta-
tistically significant difference (p=0.012)
(40). In addition, 6 of the 7 cancer cases
had elevated serum p21 prior to the time
of clinical diagnosis (average= 16.3
months), again suggesting that this may be
a biomarker ofearly malignant disease in
certain cases. In another study, elevated
serum p21 by immmunoblotting was
found in up to 54 of 80 (67.5%) cases of
various cancers (including lung, colon,
breast, prostate, and liver) compared to 30
of 188 (15.9%) non-cancer controls, a sta-
tistically significant difference (85). In a
recent study, elevated plasma p21 by
immunoblotting was found in 4 of 47
(8.5%) controls, 10 of 54 (18.5%) colonic
adenoma cases, and 9 of 22 (40.9%)
colonic carcinoma cases, a statistically sig-
nificant difference between cancers and
controls (p= 0.003) (86). In this study,
plasma p21 overexpression increased with
increasing size ofadenoma and increasing
stage of carcinoma, and there was a sta-
tistically significant correlation between
overexpression in the plasma and in the
corresponding tumor tissue.
Mutant ras p21 protein has also been
detected in blood. Asp 13 mutant p21 was
studied by immunoblotting in the serum
ofpatients with angiosarcoma ofthe liver
(ASL) and in individuals with heavy vinyl
chloride (VC) exposure who are at risk for
the development ofASL (87,88). In this
study, four offive (80%) cases ofASL were
found to contain the mutant ras gene in
their tumor tissue and to express the corre-
sponding mutant p21 in their tumor tissue
and in their serum, whereas the one case of
ASL without the mutation and a case of
hepatocellular carcinomawithout the muta-
tion did not have detectable mutant p21 in
their tumor tissue or in their serum. In one
ofthe ASL cases with multiple serum sam-
ples over time, levels of mutant p21
appeared to correlate with the clinical status
ofdisease. In addition, 8 of9 (89%) indi-
viduals with VC-associated, nonmalignant
angiomatous lesions ofthe liver and 22 of
45 (49%) individuals with heavy VC expo-
sure but no detectable liver lesions also had
mutant p21 in their serum compared to 0
of 28 (0%) controls matched for age, sex,
and race. Stratification of this cohort by
years ofVC exposure showed a significant
linear trend (p< 10-5) for the occurrence of
the serum mutant p21 with increasing
duration ofexposure, and, since increased
exposure is associated with increased cancer
risk, this suggests that serum mutant p21
may be a biomarker ofearly carcinogenic
change in some cases.
Other biomarkers of ras gene mutation
have also been identified in blood. For
example, the identification of mutant ras
genes by polymerase chain reaction and
direct sequencing of DNA isolated from
the serum or plasma ofthree patients with
pancreatic cancer has been described (89).
Furthermore, circulating antibodies
directed against Asp 12 mutant p21 have
been detected by ELISA in 51 of 160
(32%) colon cancer patients compared to 1
of 40 (2.5%) normal controls (90).
Elevated levels of the ras p21 protein as
well as mutant forms have also been identi-
fied by immunoblotting in the urine of
cancer patients (3,91).
The myc oncogene encodes a 64-kDa
nuclear protein that forms a heterodimer
with the max oncogene protein and binds
to specific DNA sequences, resulting in the
transcription of other genes involved in
controlling the cell cycle. Overexpression
ofthe myc oncoprotein has been noted in
many human malignancies, and increased
levels have been detected in blood. For
example, increased myc-related protein has
been identified in the serum by im-
munoblotting in 51 patients with a wide
variety of solid tumors compared to 16
controls with nonmalignant disease and 17
healthy controls (92,93). In 12 of the
cancer cases, localization ofthe production
of the myc protein to the tumor was
demonstrated in vivo by radioimmuno-
scintigraphy, and serial measurements in
patients with resected colorectal carcino-
mas showed agradual return to normal lev-
els following surgery. In another study,
increased levels ofmyc protein were identi-
fied by immunoblotting in 7 of36 (19%)
breast cancer cases compared to 0 of 25
(0%) matched controls, a statistically sig-
nificant difference (p= 0.02) (51,94). In
two cases, increased myc protein was also
identified in the tumor tissue, and in one
case, increased serum levels returned to
normal following the removal of the
tumor. In addition, one case ofintraductal
carcinoma without evidence of invasion
was serum-positive for myc protein, sug-
gesting that this may be a biomarker of
early malignant disease in some cases.
Serum antibodies to the myc protein have
also been identified in cancer patients. For
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example, circulating myc antibodies were
first described in 4 of6 (67%) colon can-
cers, 12 of125 (10%) breast cancers, 1 of2
(50%) osteosarcomas, 1 of9 (11%) ovarian
cancers, and 3 cancers ofunknown origin
(95). A follow-up study demonstrated myc
antibodies in serum of 25 of 44 (57%)
cases ofcolorectal cancer compared to 8 of
46 (17%) normal controls (p=0.001)
(96). Antibodies to the myc protein have
also been described in the sera ofpatients
with myeloid leukemia and lymphoma,
including Burkitt's lymphoma (97). Serum
antibodies to other oncogene proteins have
also been identified in cancer patients (98).
TumorSuppressor GeneProteins
The most frequent site for mutations in
human cancers is the tumor suppressor
gene encoding p53, a 53-kDa nuclear
phosphoprotein. The effect ofthese muta-
tions is to cause loss ofthe normal growth
inhibitory function ofp53 with a concomi-
tant accumulation ofthe mutant proteins
in the transformed cells due to the consid-
erably increased half-lives of mutant p53s.
Accumulations ofmutant p53 have been
frequently identified by immunohisto-
chemistry in human tumors and in some
cases lead to accumulations in the extracel-
lular environment resulting in potential
biomarkers in the blood.
Increased levels ofmutant p53 in serum
determined by ELISA (greater than 0.3
ng/ml, the upper limit of 100 normals) was
first reported in 11 of 54 (20%) patients
with hepatocellular carcinoma as well as
30% of patients with cirrhosis, a group
known to be at increased risk for the devel-
opment ofhepatocellular carcinoma (99).
Elevated serum mutant p53 levels deter-
mined by ELISA have also been reported
in 5 of60 (8%) breast cancer patients, with
levels decreasing following surgical re-
section of the tumors, although tissue
immunochemistry for p53 correlated
poorly with serum levels (100). In another
study, elevated serum mutant p53 by
ELISAwas found in 15 of82 (18%) breast
cancer patients compared to 0 of 20 (0%)
normals (101). Elevated serum mutant
p53 levels determined by ELISA and
immunoblotting were also found in 3 of
23 (13%) lung cancer patients compared
to 0 of23 (0%) controls matched for age,
sex, and race and 2 of58 (3%) unmatched
controls, and increased tissue p53 and/or
the presence ofp53 gene mutations were
found in the 3 serum-positive cancer cases
(102). In a larger study of lung cancer
patients, elevated levels ofmutant p53 were
detected by ELISA in the serum of 17 of50
(34%) non-small cell lung cancer patients
compared to 0 qf 15 (0%) controls, and the
levels ofp53 protein accumulation in the
tumor tissue by immunohistochemistry
were found to be strongly correlated with
the levels ofp53 in the serum (p=0.007)
(103). Elevated levels ofmutant p53 have
also been reported in the plasma of21 of
65 (32%) patients with non-Hodgkin's
lymphoma (104) and in the serum of6 of
33 (18%) patients with Hodgkin's lym-
phoma (105). In another study, elevated
total serum p53 protein (greater than 10
controls) was reported in 6 of 16 (38%)
patients with colonic adenomas and 18 of
28 (64%) patients with colonic carcinomas
(106). In another study of colonic neo-
plasms, plasma levels ofmutant p53 were
found to be statistically significantly ele-
vated among 54 cases ofcolonic adenomas
(mean = 0.44 ng/ml) and 22 cases of
colonic carcinomas (mean = 0.55 ng/ml)
compared to 47 individuals with negative
colonoscopic examinations (mean=0.12
ng/ml) (p<0.02), and plasma levels tended
to increase with increasing adenoma size
and increasing carcinoma stage (107).
Total serum p53 levels have also been
found to be statistically significantly ele-
vated among 22 former uranium miners
with lung cancer compared to 7 healthy
controls (p= 0.003) (74). In a study of
banked serum samples from asbestosis
patients, elevated total and mutant serum
p53 was found in up to 6 of 32 (19%)
patients who subsequently developed
cancer compared to 2 of36 (6%) asbestosis
patients without cancer and 1 of 10 (10%)
nonasbestosis controls; in 1 serum-positive
case oflung cancer, elevated p53 levels were
found in the tumor tissue, and in several of
the cases elevated levels were present in
serum years prior to the dinical diagnosis of
disease (8,108). Serum mutant p53 has also
been examined in vinyl chloride-exposed
workers with and without angiosarcomas of
the liver. Two cases ofASL known to con-
tainp53gene mutations were found to have
elevated serum mutant p53 by ELISA com-
pared to 2 cases ofASL and the one case of
hepatocellular carcinoma known not to con-
tain p53 gene mutations. In addition, 3 of
19 (16%) VC-exposed workers without
liver lesions were also serum-positive for
mutant p53 compared to 0 of 5 (0%)
matched unexposed controls (109). These
results, together with those on banked
serum samples, suggest that serum p53 may
be a biomarker ofearly malignant change in
some cases. Other studies, however, have
failed to detect elevated serum p53 in cancer
patients (110).
Serum antibodies against p53 have also
been reported in patients with several types
of cancer. p53 antibodies in serum were
first reported in 14 of 155 (9%) breast
cancer patients compared to 0 of 164 (0%)
controls (111). Fromentel et al. reported
p53 antibodies in the sera of 14 of 119
(12%) children with various types of
cancer, including 6 of28 (21%) cases ofB-
cell lymphoma, compared to 1 of88 (1%)
controls (112). p53 antibodies have been
found in the sera of6 of46 (13%) patients
with lung cancer compared to 0 of 51
(0%) controls, and in this study, all anti-
body-positive cases had p53 gene missense
mutations and increased p53 protein in
their tumors (113). Similarly, p53 anti-
bodies have been found in the sera of7 of
60 (11%) patients with breast cancer com-
pared to 0 of 15 (0%) controls, and all 7
positive cases had p53 gene mutations and
increased p53 protein in their tumors
(114). Schlichtholz et al. also reported p53
antibodies in the sera of 15 of 100 (15%)
patients with breast cancer (115). p53
antibodies were reported in the serum in 9
of 175 (5%) patients with various cancers
(including colon, breast, lung, and ovary)
compared to 0 of22 (0%) controls (116).
In another study, p53 antibodies were
identified in serum in 20 of 80 (25%)
patients with hepatocellular carcinoma
compared to 0 of67 (0%) controls (117).
Antibodies to p53 have also been found in
the serum in 12 of93 (13%) breast cancer
patients, 2 of 83 (2%) prostate cancer
patients, 4 of 108 (4%) thyroid cancer
patients, 10 of 42 (24%) lung cancer
patients, 8 of 29 (28%) bladder cancer
patients, 4 of 88 (5%) leukemia patients,
14 of73 (19%) pancreas cancer patients,
and 1 patient each with ovarian cancer,
hepatoma, and kidney cancer (118). In
another study, p53 antibodies were found
in the sera of 10 of42 (24%) patients with
lung carcinoma compared to 2 of 58 (3%)
controls with nonmalignant respiratory
diseases, but one ofthe positive controls
was found to have a tracheal chondroma
and the other was diagnosed with lung
cancer 4 months later, suggesting that p53
antibodies may be an early marker ofneo-
plasia in certain cases (119). Angelopolou
and Diamandis reported p53 antibodies in
serum determined by two different meth-
ods in 3 of 105 (3%) breast cancer
patients, 10 of 22 (14%) ovarian cancer
patients, 11 of 77 (14%) colon cancer
patients, and 2 of46 (4%) pancreas cancer
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patients (120). Mudenda et al. reported
p53 antibodies in the serum of48 of 182
(26%) breast cancer patients compared to
1 of76 (1.3%) normal controls, and there
was a significant correlation between serum
positivity and increased p53 protein in the
tumor; in addition, 8 of23 (35%) patients
with ductal carcinoma in situ were positive
for p53 antibodies, again suggesting that
this may be an early marker ofdisease in
some cases (121). In a large recent study of
p53 antibodies in serum in 1392 patients
with various malignancies determined by
two methods, the highest prevalence of
antibodies was found in ovarian and colon
cancers (15%), lung cancers (8%) and
breast cancers (5%) with lower prevalences
in other malignancies (<4%) and controls
(< 1-2%) (122). In a study ofvinyl chlo-
ride-exposed workers, 9 patients with ASLs
were found to have p53 antibodies in their
serum, and in 3 cases these were detectable
prior to the clinical detection of disease
(average= 8 years), once again supporting
the hypothesis that this may be an early
biomarker ofdisease in certain cases (123).
Finally, another recent study reported p53
antibodies in serum by two different
ELISAs in 16 of 136 (11.8%) lung cancer
patients compared to 0 of52 (0%) patients
with nonmalignant pulmonary disease;
however, although 47 of the tumors con-
tainedp53 gene mutations, only 7 ofthose
were antibody positive, and of 32 tumors
with accumulations ofp53 protein, only 5
were antibody positive (124).
Summary
The research summarized here suggests
that the expression of genes involved in
growth-signal transduction, as determined
by detection ofgrowth factors and onco-
proteins in easily accessible extracellular
fluids, may represent convenient biomark-
ers for monitoring related disease processes,
particularly cancer (for summary see Table
1). In some cases, these biomarkers not
only have shown the ability to distinguish
between diseased and nondiseased states
but also have suggested the possibility of
detection early in the disease process
indicating susceptibility to future develop-
ment of disease. By and large, however,
these studies have focused on acquired
defects in the expression of these growth
factors and oncoproteins rather than on
inherited defects, which would be more
typical for other susceptibility biomarkers.
Nevertheless, the potential exists for the
application of these assays for detecting
related inherited defects, for example, in
Table 1. Summ
Biomarker
Growth factors
PDGF
TGFa
TGFO
bFGF
EGF
IGF
HGF
Oncoproteins
erbB-2
iary of studies ofgrowth factors and oncoproteins as extracellular biomarkers of gene expression.
Method of analysis Associated diseases References
ELISA, RIA, and immunoblot
in plasma, serum,
urine, or bronchoalveolar
lavage
ELISA and RIA in
plasma, serum, cyst
aspirates, or effusions
ELISA, immunoblot and
activity assay in plasma,
serum, or cyst aspirates
ELISA and other EIA
in serum or plasma
RIA in plasma, serum,
urine, orcyst aspirates
ELISAand RIA in
plasma or serum
ELISA in serum
ELISA and RIA in serum
or plasma
erbB-2Ab Immunoprecipitation of
supernatant of cultured
lymphocytes
EGFR
ras
ras Ab
myc
myc Ab
myb Ab
p53
p53 Ab
ELISA in serum or
urine
ELISA, immunoblot, and
PCR in serum, plasma,
or urine
ELISA in serum
Immunoblot in serum
Immunoblot in serum
Immunoblot in serum
ELISA, immunoblot, and
immunofluorometry in
serum or plasma
ELISAand immunoblot
in serum
individuals with inherited mutations in p53
in the Li-Fraumeni syndrome and in other
elevated risk circumstances. For instance, a
recent study identified increased levels of
the extracellular domain of the erbB-2
oncoprotein in healthy asymptomatic
women to be associated with other
established risk factors for breast cancer,
including a family history of a grand-
mother with breast cancer, among others
(52). These assays may thus be able to
detect both acquired and inherited suscep-
tibility states. In addition, many of the
Breast cancer, various
other carcinomas, sarcomas,
lymphomas, lung fibrosis,
pneumoconiosis, atherosclerosis
Breast cancer, various
other carcinomas,
pneumoconiosis
Livercancer, bladdercancer,
breast cancer, leukemia,
liverand lung fibrosis,
pneumoconiosis
Kidney cancer, breast
cancer, various other cancers
Stomach cancer, ovarian
cancer, various other cancers
Breast cancer, ovarian
cancer, hepatitis, cirrhosis
Liver cancer, hepatitis, cirrhosis
Breast cancer, ovarian cancer,
liver cancer, lung cancer,
various other cancers
Breast cancer
Lung cancer, various
other carcinomas
Lung cancer, colon cancer,
angiosarcoma of liver,
various other cancer
Colon cancer
Lung cancer, colon
cancer, breast cancer
Colon cancer, breast
cancer, lymphoma,
various othercancers
Various cancers
Lung cancer, breast cancer,
colon cancer, liver cancer,
lymphoma
Lung cancer, breastcancer,
colon cancer, livercancer,
leukemia, lymphoma,
various other cancers
(1-3,37,40,41)
(4-8,34,35)
(9-13,35,38,39)
(14-22)
(23-28,33,36)
(25,29-31)
(32)
(42-60, 62-71)
(61)
(72-75)
(3,40,76-89,91)
(90)
(52,92-94)
(95-97)
(98)
(8,74,99-110)
(111-124)
assays involved are relatively simple and
straightforward immunologic analysis tech-
niques amenable for routine use in any
hospital laboratory, including those in
developing counties. However, additional
study will be necessary before these assays
can be considered for such routine use.
Further work will be required in terms of
standardization ofassay techniques, corre-
lation ofblood and tissue expression, the
kinetics of release from cells and elimina-
tion from the blood, assay reproducibility,
stability ofstored samples, better definition
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of significant blood levels in terms of
pathophysiologic importance and in rela-
tion to the range of normal values deter-
mined in large populations, definition of
potential confounding factors, and assess-
ment ofsensitivity, specificity, and predic-
tive value of the tests. Recent advances
suggest that detection sensitivity for
many of these assays can be greatly
improved in the near future, which could
help to resolve some of these issues. For
example, the combination of current
immunochemical techniques with DNA
amplification technology based on the
polymerase chain reaction (immuno-PCR)
offers the prospect ofincreasing sensitivity
by 100,000-fold or more (125). Ultimately,
highly sensitive, specific, standardized
assays for growth factors and oncoproteins
(alone or in combinations) could be valu-
able tools for monitoring at-risk popula-
tions for purposes of disease prevention
and control.
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